Publications
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
31 March 2026
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, and is responsible for substantial health and economic burden to health systems and wider society.
The case for adopting a broader perspective on value in Health Technology Assessment
3 March 2026
In this Whitepaper, we describe different perspectives that can be adopted in Health Technology Assessment (HTA), and some of the advantages and disadvantages of these different…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple myeloma and cancer as a whole. The…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by targeting molecular alterations regardless of tumour histology.
Capturing the lived experiences of informal care in acute leukemia
20 November 2025
Providing informal care to someone living with acute leukemia imposes a severe multidimensional burden, reshaping relationships and affecting mental health, physical health, career, finances, social activities and more.
The commercial case for investing in ALS
13 November 2025
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE) framework through a structured, multidisciplinary stakeholder engagement process.
Patient preferences for treatment in relapsed/refractory acute leukemia
23 October 2025
When acute leukemia relapses, treatment decisions can be complex. Patients may face trade-offs between survival benefits, side effects and how treatment is delivered. This study asked people with acute leukemia across five countries what matters most to them when making these choices.
The value of cell and gene therapies to the UK economy
20 October 2025
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are already licensed worldwide and over two thousand are in clinical development.